Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 11/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 10/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | WDR5 | P61964 | 4/20 | 0.32 |
| ▸ | BTK | Q06187 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14069434 | 1.00 | CDK9 (0.36) | CDK9CCNT1MAPK1WDR5BTK | |
| SCHEMBL9929903 | 0.88 | WDR5 (0.30) | WDR5 | |
| SCHEMBL14069649 | 0.88 | WDR5 (0.30) | WDR5 | |
| SCHEMBL14069896 | 0.88 | CCNT1 (0.37) | CDK9CCNT1MAPK1WDR5BTK | |
| SCHEMBL9929970 | 0.88 | CCNT1 (0.37) | CDK9CCNT1MAPK1WDR5BTK | |
| SCHEMBL4555118 | 0.83 | MAOA (0.39) | CDK9CCNT1MAPK1WDR5BTK | |
| SCHEMBL9930041 | 0.82 | MAOB (0.47) | CDK9CCNT1MAPK1WDR5BTK | |
| SCHEMBL9930385 | 0.82 | CCNT1 (0.36) | CDK9CCNT1MAPK1WDR5 | |
| SCHEMBL9929656 | 0.81 | MAOA (0.39) | CDK9CCNT1MAPK1WDR5BTK | |
| SCHEMBL9968668 | 0.81 | CCNT1 (0.40) | CDK9CCNT1WDR5BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | CSO of MicuRx Pharmaceuticals, Inc. | 2012-06-21 | — | — | US | disclosed |
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | CSO of MicuRx Pharmaceuticals, Inc. | 2012-06-21 | — | — | US | disclosed |
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | CSO of MicuRx Pharmaceuticals, Inc. | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | NISCH, NOD1, NQO1 | CDK9 1980/4885CCNT1 775/4885MAPK1 3022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.